This article is more than 5 years old. Information may no longer be current.
Top stories in hematology/oncology: FDA links more lymphoma cases to breast implants, USPSTF recommends against pancreatic cancer screening in asymptomatic adults
Click Here to Manage Email Alerts
Among the top hematology/oncology stories last week were the FDA’s identification of more cases of breast implant-associated lymphoma and the USPSTF’s draft recommendation that adults without family history, signs or symptoms of pancreatic cancer should not be screened for the disease.
Other highlights included a study that found young adults in the U.S. are at a higher risk for obesity-related cancers than previous generations, the FDA granting Kadcyla breakthrough therapy designation for the adjuvant treatment of patients with HER2-positive early breast cancer who have residual disease after neoadjuvant treatment and phase 3 trial results that demonstrated isatuximab prolonged progression-free survival for patients with relapsed or refractory multiple myeloma.
FDA identifies more cases of breast implant-associated lymphoma
The number of lymphoma cases linked to breast implants increased approximately 10% in the past year, according to the FDA. Read more.
USPSTF maintains stance against pancreatic cancer screening in asymptomatic adults
Adults without family history, signs or symptoms of pancreatic cancer should not be screened for the disease, according to a draft recommendation issued by the U.S. Preventive Services Task Force. Read more.
Risk for obesity-related cancers rising among young adults
Young adults in the U.S. demonstrated a higher risk for obesity-related cancers than previous generations, according to a study recently published in Lancet Public Health. Read more.
FDA grants Kadcyla breakthrough therapy designation for HER2-positive early breast cancer
The FDA granted ado-trastuzumab emtansine breakthrough therapy designation for the adjuvant treatment of patients with HER2-positive early breast cancer who have residual disease after neoadjuvant treatment. Read more.
Isatuximab prolongs progression-free survival in relapsed or refractory multiple myeloma
A randomized phase 3 trial designed to evaluate the addition of isatuximab to a standard treatment for patients with relapsed or refractory myeloma met its primary endpoint of progression-free survival. Read more.